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Diabetic macular edema (DME), pseudophakic cystoid macular edema (CME), age-related macular degeneration (AMD), retinal
vascular occlusion (RVO), and uveitis are ocular conditions related to severe visual impairment worldwide. Corticosteroids have
been widely used in the treatment of these retinal diseases, due to their well-known antiangiogenic, antiedematous, and anti-
inflammatory properties. Intravitreal steroids have emerged as novel and essential tools in the ophthalmologist’s armamentarium,
allowing formaximization of drug efficacy and limited risk of systemic side effects. Recent advances in ocular drug deliverymethods
led to the development of intraocular implants, which help to provide prolonged treatment with controlled drug release. Moreover,
theymay add some potential advantages over traditional intraocular injections by delivering certain rates of drug directly to the site
of action, amplifying the drug’s half-life, contributing in the minimization of peak plasma levels of the drug, and avoiding the side
effects associated with repeated intravitreal injections. The purpose of this review is to provide an update on the use of intravitreal
steroids as a treatment option for a variety of retinal diseases and to review the current literature considering their properties, safety,
and adverse events.
1. Introduction
The use of corticosteroids for the treatment of ocular inflam-
matory diseases was first described in the early 1950s [1].
Corticosteroids have anti-inflammatory, antiangiogenic, and
antipermeability properties that make them an attractive
therapeutic option for a variety of posterior segment diseases.
The rationale for using a steroidal drug for the treatment
of edematous and proliferative diseases is that abnormal
proliferation of cells is often associated with and trigged by
inflammation.Moreover, intraretinal accumulation of fluid is
usually accompanied by a blood-retinal barrier dysfunction
that can be restored with steroid therapy.The principal effects
of steroids are thought to be stabilization of the blood-retinal
barrier (BRB), reduction of exudation, and downregulation
of inflammatory stimuli, but the exact mechanisms remain
unknown. Steroids are thought to act by the induction
of proteins called lipocortins, in particular phospholipase
A2. These proteins reduce leukocyte chemotaxis, control
biosynthesis, and inhibit the release of arachidonic acid
from the phospholipid membrane, which is one of the most
important common precursors of potent inflammatory cell
mediators such as prostaglandins and leukotrienes. Based
on experimental studies, corticosteroids have been shown
to control gene expression of inflammatory mediators. This
regulation influences the expression of vascular endothe-
lial growth factor (VEGF), inhibits pro-inflammatory genes
such as tumor necrosis factor-alpha (TNF-𝛼) and other
inflammatory chemokines, and induces the expression of
anti-inflammatory factors such as pigment-derived growth
factor (PEDF) [2–4]. Additionally, steroids seem to reduce
the expression of matrix metalloproteinases (MMPs) and
to downregulate intercellular adhesion molecule 1 (ICAM-
1) on choroidal endothelial cells [5–11]. Several routes of
administration have been considered for the treatment of
various ocular diseases. Oral dosing, unfortunately, causes
a spectrum of systemic side effects, including osteoporo-
sis, cushingoid state, adrenal suppression, and exacerba-
tion of diabetes [12, 13]. Topical steroids have not been
shown to penetrate adequately to the posterior segment [14].
Geroski and Edelhauser reported that therapeutic doses of
steroids could reach the posterior segment via transscleral
absorption with periocular administration [15]. Thus, other
routes of administration, such as subconjunctival, subtenon,
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and posterior juxtascleral infusions, have been studied [16–
18]. Periocular delivery of steroids has offered for many years
a valid compromise between better penetration and lack of
systemic side effects. However, peribulbar injections seem to
result in lower morphological and functional outcomes as
compared with those reported with the use of intravitreal
administration [19–22]. But, two interventional case series
have demonstrated that posterior juxtascleral infusion of a
viscoelastic formulation of triamcinolone acetonide is an
effective treatment for diffuse diabeticmacular edema (DME)
unresponsive to laser photocoagulation [23, 24].
Based on experimental studies, clinical observations,
and pathogenic considerations, Robert Machemer, among
others, suggested the intravitreal delivery of steroids to
locally suppress intraocular inflammation, proliferation of
cells, and neovascularization [25]. Intravitreal delivery of
corticosteroids has allowed many posterior segment diseases
to be locally treated without the adverse systemic side effects.
Intravitreal steroids have been widely studied in many ran-
domized clinical trials, demonstrating significant improve-
ments both in morphological and functional outcomes in
many posterior segment diseases [26–28]. Intravitreal ther-
apy also allows for the steroid to bypass the BRB, leading to
a more concentrated dose of steroid for a prolonged period
of time. Delivery of steroids to the vitreous cavity can be
achieved via direct injection through the pars plana, intro-
duction of a sustained-release or biodegradable implants,
or injection of conjugate compounds. Several intravitreal
biodegradable and nondegradable steroid releasing implants
have been designed to provide long-term drug delivery
to the macular region. Different steroid molecules have
varying potencies and toxicities. There are several ways
to distinguish among the steroids used in ophthalmology,
including chemical structure, anti-inflammatory potency,
ability to translocate the glucocorticoid receptor complex to
the nucleus, ability to transactivate or transrepress ligand-
dependent gene sets and biologic responses, neuroprotection
of the photoreceptors/retinal pigment epithelium, and direct
cytotoxic effects [29]. These differences may help to explain
the differences among steroids in their safety and efficacy
for the treatment of retinal disease. The purpose of this
paper is to review the current status of intravitreal steroidal
drugs, including triamcinolone acetonide, biodegradable
dexamethasone implant, and nondegradable fluocinolone
acetonide implant in the treatment of various retinal diseases
such as diabetic macular edema (DME), central and branch
retinal vein occlusion (CRVO and BRVO), neovascular age-
related macular degeneration (AMD), pseudophakic cystoid
macular edema (CME), and macular edema secondary to
uveitis.
2. Triamcinolone Acetonide
Triamcinolone acetonide (TA) is a synthetic steroid of the
glucocorticoid family with a fluorine in the ninth position
[30]. It is commercially available as an ester and represents
one of the most commonly used steroid agents for the
treatment of several retinal conditions [31]. TA has an
anti-inflammatory potency five times higher than hydro-
cortisone with a tenth of the sodium-retaining potency. It
appears as a white- to cream-colored crystalline powder
and it is practically insoluble in water and very soluble in
alcohol [14]. The decreased water solubility accounts for
its prolonged duration of action. It has been observed that
adequate concentrations of TA could provide therapeutic
effects for approximately three months after 4mg intravitreal
TA injection [32]. Maximum effect duration of 140 days has
been suggested [33].
The current commercial preparations of TA include prod-
ucts that received dermatologic and orthopedic indications
and are considered off-label for the intraocular use, products
registered as devices for assisting the visualization of the
vitreous during vitreoretinal procedures, and products that
are registered for intraocular use in uveitis, and other ocular
inflammatory conditions. Kenalog-40 (40mg/mL, Bristol-
Myers Squibb, NJ) is the most commonly used intraocular
steroid and has been widely utilized as intravitreal injections
since 2004 for the treatment of several retinal diseases. This
formulation is US Food and Drug Administration (FDA)-
approved only for intramuscular and intra-articular use
and is currently employed off-label for intraocular injec-
tions. TrivarisTM (80mg/mL, Allergan Inc., Irvine, CA)
and Triesence (40mg/mL, Alcon Inc., Fort Worth, TX) are
preservative-free brands of TA recently FDA approved for
ophthalmic use in the treatment of sympathetic ophthalmia,
temporal arteritis, uveitis, and other ocular inflammatory
diseases, unresponsive to topical corticosteroids. Vitreal S
(Sooft s.p.a., Fermo, Italy) is a medical device used in
endocular surgery to stain the vitreous during vitrectomy
and it is not registered as drug for intraocular use. There
are some issues regarding the formulation of TA used
for intraocular administration. A previous phase-contrast
microscopy study showed a notable difference of crystal size
depending upon the drug formulation [34]. Very large and
irregular crystals, with a significant heterogeneity in crystal
size, were occasionally found in the off-label, commercially
available, benzyl-alcohol-preserved TA, whereas the crys-
tals of a preservative-free in-label, commercially available,
TA suspension appeared to be relatively uniform in size.
These morphologic aspects may have a significant impact
on the half-life of the drug both in vivo and in vitro. This
hypothesis is based on the fact that smaller crystals have a
superior surface-area-to-volume ratio, allowing them to be
dissolved more rapidly. The formulations containing crystals
that widely vary in size and, thus, including larger crystals
may theoretically generate a wider time–drug concentration
curve because of their slower dissolution rate. Different TA
formulations show variance in reducing the endothelial cell
proliferation.
The appropriate dose of intravitreal TA remains a subject
of debate. Both Audren et al. and Hauser et al. showed that
the use of a 4mg dose of intravitreal TA does not have
enough advantages over the lower 1mg or 2mg dose [35,
36]. However, Lam et al. published a comparison between
4mg and 8mg doses and showed that the higher dose had
a more sustained effect on both visual acuity and central
macular thickness, although with a trend to more ocular
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complications [37]. By using a dose of about 20mg of TA, the
increase in visual acuity was mostly marked during the first
three and six months after injection and was observable for
a period of about six to nine months. Differently, by using
a dose of 4mg, the duration in the reduction of macular
thickness as measured by optical coherence tomography
(OCT) was less than six months [38].
Based on several studies, intravitreal administration of
triamcinolone acetonide (TA) has provided promising results
for the treatment of disorders associated with an abnormal
endothelial cell proliferation and conditions complicated
by intraretinal and subretinal fluid accumulation. The anti-
inflammatory, angiostatic, and antipermeability properties
of TA have gained interest in chronic retinal diseases, such
as proliferative diabetic retinopathy [39], DME [40, 41],
exudative AMD [42–44], presumed ocular histoplasmosis
syndrome [45], CRVO [46], BRVO [47], neovascular glau-
coma [48], proliferative vitreoretinopathy [49], persistent
pseudophakic CME [50], perifoveal telangiectasias [51], sym-
pathetic ophthalmia [52], ischemic ophthalmopathy [53],
exudative retinal detachment [54], radiation induced macu-
lar edema [55], macular edema due to retinitis pigmentosa
[56], Vogt-Koyanagi-Harada syndrome [57], and chronic
uveitis [58].
2.1. DiabeticMacular Edema. Intravitreal TA has beenwidely
studied in many randomized clinical trials on DME demon-
strating significant improvements both in morphological
and functional outcomes [40, 41, 59–61]. Focal and grid
laser photocoagulation have been considered the standard
of care for the treatment of DME for many years. However,
a substantial group of patients are unresponsive to laser
therapy and fail to improve after photocoagulation. It has
been reported that three years after initial grid treatment,
visual acuity improved in 14.5% of the eyes, did not change
in 60.9%, and decreased in 24.6% of patients with DME [59].
Therefore, TA has been tested for the treatment of DME,
either na¨ıve or diffuse and refractory to laser therapy. In most
cases, TA has been administered intravitreally.
A carefully designed prospective randomized trial con-
ducted by the Diabetic Retinopathy Clinical Research Net-
work (DRCR.net) investigated the efficacy and safety of 1-mg
and 4-mg doses of preservative-free intravitreal TA (Trivaris)
in comparison with focal or grid laser photocoagulation [60].
In the DRCR.net study, 840 study eyes affected by DME were
randomized to either focal or grid laser photocoagulation
(𝑛 = 330), 1mg TA (𝑛 = 256) or 4mg TA (𝑛 = 254). At 36
months, the mean change in the visual acuity from baseline
was +5 letters in the laser group and 0 letters in both TA
groups. A worsening in visual acuity of three or more lines
occurred in 8%, 17%, and 16% of eyes, respectively, and an
improvement in visual acuity by three or more lines occurred
in 26%, 20%, and 21% of eyes, respectively. Mean (±SD)
reductions in central macular thickness were 175 ± 149 𝜇m
in the laser group, 124 ± 184 𝜇m in the 1mg TA group, and
126 ± 159 𝜇m in the 4mg TA group. The mean number of
treatments at the end of the follow-up was 3.1 for the laser
group, 4.2 for the 1mg, and 4.1 for the 4mg TA groups.
At the four-month visit, mean visual acuity improvement was
higher in the 4mg TA group (4 ± 12 letters improvement)
than in either the laser group (0 ± 13 letters change) or
the 1mg TA group (0 ± 13 letters change). By 12 months,
there were no significant differences among groups in mean
visual acuity. Therefore, in this study, photocoagulation was
shown to be more effective over time and had fewer side
effects than TA. This was considered in support of focal/grid
photocoagulation. However, it must be noted that during
the 36 months of follow-up, patients received only four
treatments with intravitreal TA, which is a low reinjection
rate based on pharmacokinetic data. Recently, a new, large,
randomized DRCR.net study investigated the efficacy of
intravitreal TA in combination with laser photocoagulation
in comparison with intravitreal ranibizumab with prompt
or deferred laser photocoagulation or laser photocoagulation
alone. At 2-year visit, mean change (±SD) in the visual acuity
letter score from baseline was +7 ± 13 in the ranibizumab
+ prompt laser group, +9 ± 14 in ranibizumab + deferred
laser group, +2 ± 19 in the TA + prompt laser group, and
+3 ± 15 the sham + prompt laser group. Compared with the
sham + prompt laser group, the difference in mean change
in the visual acuity letter score from baseline was 3.7 letters
greater in the ranibizumab + prompt laser group (𝑃 = 0.03),
5.8 letters greater in the ranibizumab + deferred laser group
(𝑃 < 0.01), and 1.5 letters worse in the TA + prompt laser
group (𝑃 = 0.35). A worsening of visual acuity of three
or more lines occurred in 10%, 4%, 2%, and 13% of eyes,
respectively, and an improvement in visual acuity by three
or more lines occurred in 18%, 29%, 28%, and 22% of eyes,
respectively. The mean change (𝜇m ± SD) in central retinal
thickness from baseline was −141±155 in the ranibizumab +
prompt laser group, −150 ± 143 in ranibizumab + deferred
laser group, −107 ± 145 in the TA + prompt laser group,
and −138 ± 149 the sham + prompt laser group. Compared
with the sham + prompt laser group, the difference in mean
change in central macular thickness from baseline was 31 𝜇m
worse in the ranibizumab + prompt laser group (𝑃 = 0.03),
28𝜇m worse in the ranibizumab + deferred laser group (𝑃 =
0.01), and 10 𝜇m worse in the TA + prompt laser group (𝑃 =
0.37).These results showed that intravitreal ranibizumabwith
prompt or deferred laser is more effective than prompt laser
alone or intravitreal TA combinedwith laser for the treatment
of DME involving the central macula. Among the eyes that
were pseudophakic at baseline, the mean change (±SD) in
the visual acuity letter score from baseline was +5 ± 17 in the
ranibizumab + prompt laser group, +9±17 in ranibizumab +
deferred laser group, +8 ± 13 in the TA + prompt laser
group, and +5 ± 15 the sham + prompt laser group. The
difference in mean change in visual acuity letter score from
baseline to the two-year visit was 1.6 letters greater in the TA
+ prompt laser group comparedwith the sham+prompt laser
group and was similar to difference in outcomes between
the ranibizumab + prompt laser group (+0.5 letters) and the
ranibizumab + deferred laser group (+3.5 letters) compared
with the sham + prompt laser group. Cataract surgery was
required in 12% of phakic eyes in the sham+prompt laser and
in the ranibizumab + prompt laser groups, in 13% of phakic
eyes in the ranibizumab + deferred laser group, and in 55%
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of patients of the TA + laser group. An intraocular pressure
(IOP)-lowering medication was required in 5% of eyes in the
sham+ prompt laser and ranibizumab + prompt laser groups,
in 3% of eyes in the ranibizumab + deferred laser group, and
in 28% of patients of the TA + laser group [61]. Other studies
demonstrated promising results of combination therapy with
intravitreal injection of TA and laser photocoagulation for
the treatment of proliferative diabetic retinopathy (PDR)with
clinically significantmacular edema (CSME) [62–67]. In a 12-
month randomized clinical trial conducted by Maia et al., 44
eyes with PDR and CSME were enrolled and randomized to
treatment with combined 4mg of intravitreal TA and laser
photocoagulation (𝑛 = 22) or to laser photocoagulation
alone (𝑛 = 22). Mean best correct visual acuity (BCVA)
improved significantly (𝑃 < 0.001) in the TA and laser
group compared with the laser alone group at all study
follow-up visits. An improvement of two or more Early
Treatment Diabetic Retinopathy Study (ETDRS) lines was
observed in 63.1% and 10.5% of eyes, respectively (𝑃 < 0.001).
A significant decrease in mean central macular thickness
occurred in the TA and laser group when compared with the
laser alone group at all study follow-up intervals (𝑃 < 0.001).
At 12 months, mean (±SD) reductions in central macular
thickness were 123 ± 68 𝜇m and 65 ± 51 𝜇m, respectively
(𝑃 < 0.001) [67]. Several other studies reported positive
results of intravitreal TA in refractory DME [68–71]. In a six-
month prospective, placebo-controlled, randomized clinical
trial conducted by Jonas et al., 40 eyes with persistent DME
were enrolled and randomized to treatment with 20mg TA
(𝑛 = 28) or to placebo injection (𝑛 = 12). Visual acuity
increased significantly (𝑃 < 0.001) in the TA group by
3.4 ETDRS lines. In the placebo group, visual acuity did
not change significantly (𝑃 = 0.07) during the six months.
At the end of the follow-up period, 48% in the TA group
improved by at least two ETDRS lines compared with 0%
eyes in the placebo group [69]. Recently, Gillies et al. reported
the longest-term data available concerning the outcomes of
intravitreal injection of TA. This was a five-year prospective,
double-masked, randomized clinical trial of 4mg dose of
preservative-free intravitreal TA in comparison with placebo.
In this study, 67 study eyes with refractory DME were
randomized to receive 4mg TA (𝑛 = 33) or placebo (𝑛 = 34).
At five years, an improvement in visual acuity of three or
more lines occurred in 42% of the eyes in the TA group and
32% of eyes in the placebo group (𝑃 = 0.4). A worsening of
visual acuity by three or more lines occurred in 18% and 24%
of eyes, respectively (𝑃 = 0.88). Mean (±SD) reductions in
central macular thickness were 100 ± 79 𝜇m in the TA group
and 184 ± 29 𝜇m in the placebo group (𝑃 = 0.45). After five
years, the difference in visual acuity between the two groups
was not statistically significant and there was no difference
in mean central macular thickness reduction between two
groups. Moreover, this study showed that, in the long term, a
two-year delay in the beginning of intravitreal TA treatment
did not seem to adversely affect outcomes in eyes affected
with refractory DME [70].
Novel preservative-free and sustained-release intravitreal
implants have been evaluated for the treatment of DME to
provide longer duration of pharmacologic effect with lower
administration frequency and minimal side effects. I-vation
(SurModics, Eden Prairie, MN, USA) is a nonbiodegradable,
helical, metal alloy implant coated with polybutyl methacry-
late, polyethylene vinyl acetate polymers, and TA. Drug
delivery and duration rates can be tuned varying the ratios of
the constituent polymers.This system is implanted through a
25-gauge device. A phase I study have shown positive func-
tional and morphological outcomes in 31 patients affected
by DME [71]. However, phase IIb trial for I-vation TA was
suspended in 2008 following the publication of theDRCR.net
study.TheCortiject implant (NOVA63035,Novagali Pharma)
is a preservative- and solvent-free emulsion that contains
a tissue-activated proprietary corticosteroid prodrug. Once
released, the prodrug is activated at the level of the retina.
A single intravitreal injection of the emulsion provides
sustained release of the corticosteroid over a 6- to 9-month
period. An open-label, phase 1, dose-escalation clinical study
to assess the safety and tolerability of NOVA63035 in patients
with DME is currently underway.
2.2. Macular Edema Secondary to Retinal Vein Occlusion.
Macular edema is a common cause of reduced vision in
patients with retinal vein occlusions. Due to the well-know
antiedematous and antipermeability effects, intravitreal TA
has been evaluated in many studies on macular edema sec-
ondary to CRVO and BRVO. Case series have suggested that
intravitreal injection of TA may be useful for the treatment
of macular edema in patients with BRVO [72]. However,
the use of this pharmacological approach was not sup-
ported by the results presented in the Standard Care versus
Corticosteroid for Retinal Vein Occlusion (SCORE) Study.
In this multicenter clinical trial, 411 participants affected
by macular edema secondary to BRVO were randomized
to receive laser photocoagulation, 1-mg, or 4-mg doses of
preservative-free intravitreal TA (Trivaris). After 12 months
of follow-up, the proportion of eyes with an improvement
in visual acuity that enabled patients to read 15 or more
letters was similar among the three groups (27% in the
group treated with the 4-mg dose of TA, 26% in the group
treated with the 1-mg dose, and 29% in the control group).
Results showed that there was no difference identified in
visual acuity at 12 months for the laser group compared with
the TA groups. The duration of the edema is an important
issue to be considered. Among patients with a duration of
macular edema that is more than 3 months, a proportion
of 34% of eyes showed a gain of 15 letters or more in the
4-mg TA group, versus a percentage of 15% of patients in
the photocoagulation group. However, these findings were
not statistically significant but indicated the importance of
taking into account the duration of edema in data analysis
and in clinical practice [47]. Several clinical trials have also
published the beneficial effects of intravitreal administration
of TA for the treatment of macular edema due to CRVO
[73]. In a 12-month randomized clinical trial, 271 patients
affected by macular edema secondary to nonischemic CRVO
were randomly assigned to observation, 1-mg or 4-mg doses
of preservative-free intravitreal TA (Trivaris). At 1 year, the
proportion of eyes with an improvement in visual acuity of
The Scientific World Journal 5
15 or more letters was 26% in the group treated with the 4-
mg dose of TA, 27% in the group treated with the 1-mg dose,
and 7% in the control group (𝑃 = 0.001) [46]. Verisome
(IconBioscience Inc, Sunnyvale, CA,USA) is a biodegradable
implant designed to be injected intravitreously and release TA
for up to one year.
The Verisome delivery system is a sustained-release drug
delivery system that can be injected into the eye as a liquid via
a standard 30-gauge needle. When injected into the vitreous,
the liquid coalesces into a single spherule. A phase I trial
was conducted in patients with macular edema associated
with RVO evaluating the drug delivery system at two dosing
levels, a 25-𝜇L dose designed to last 6 months, and a 50-
𝜇L dose designed to last one year in the vitreous cavity. The
promising results of the clinical trial confirmed the safety and
efficacy outcomes and the controlled-release attributes of the
technology [74].
2.3. Pseudophakic Cystoid Macular Edema. Postoperative
cystoid macular edema may be a complication of cataract
surgery. This condition is typically treated with topical,
peribulbar, and systemic administration of steroids and
nonsteroidal anti-inflammatory agents. Recently, promising
results have been obtained using intravitreal TA for the
treatment of this condition [50].
2.4. Other Indications. Intravitreal administration of TA has
been increasingly performed as an alternative option for
the treatment of exudative age-related macular degeneration
either in monotherapy or in combination with anti-VEGF
drugs. Furthermore, TA has recently been used in combi-
nation with pars plana vitrectomy for proliferative diabetic
retinopathy and proliferative vitreoretinopathy. Intravitreal
TA is also a useful surgical tool for assisting vitreoretinal
surgery because besides visualizing the vitreous body, it
allows a sharp contrast between the peeled and unpeeled
retina, promoting the removal of the membranes that are
readily visualized. TA-assisted peeling has been reported
during macular hole and macular pucker surgery [75]. Other
conditions that can benefit from intravitreal TA are uveitis
and immunological disorders, cystoid macular edema after
penetrating keratoplasty, and progressive ocular hypotony
[76, 77].
3. Dexamethasone
Dexamethasone is a potent inhibitor of cytokines released by
human pericytes and it has demonstrated high levels in the
vitreous for more than 6 months in vivo. Preclinical studies
have reported that intravitreal injection of dexamethasone
decreases significantly Intercellular Adhesion Molecule-1
(ICAM-1) mRNA, and protein levels, reducing leukostasis
and BRB breakdown [78]. Dexamethasone has a relatively
short half-life (about 3.5 hours), but is five times more potent
than TA [79, 80]. An innovative intravitreal dexamethasone
implant has been developed to permit a sustained and
extended release of corticosteroids in the intravitreal cavity.
A biodegradable dexamethasone drug delivery system (DDS)
has been created by Allergan (Ozurdex, Allergan, Irvine,
CA, USA). Ozurdex was designed to provide sustained
distribution of 700𝜇g of dexamethasone in the vitreous
cavity. The implant is formed by a solid biodegradable
polymer (NovadurTM, Allergan, Irvine, CA, USA), whose
degradation produces lactic acid and glycolic acid, which are
subsequently converted to and eliminated as carbon diox-
ide and water. The dexamethasone implant is administered
as an office-based intravitreal injection using a novel 22-
gauge injecting applicator [81]. Recently, Chang-Lin et al.
have published pharmacokinetics and pharmacodynamics
data of Ozurdex. It was observed that the opaque, round
cylindrical implant became translucent, fragmented, and
smaller two months after implantation. The concentration
of dexamethasone was detected in the retina and vitreous
humor for 6 months, with peak concentrations during the
first 2months. Dexamethasone concentrations in the vitreous
and in the retina were characterized by two distinct phases,
which corresponded to the fragmentation of the implant.
On day 60, high levels of dexamethasone were detected in
the posterior segment, with the mean peak concentration of
1110 ± 284 ng/g in the retina and 213 ± 49 ng/mL in the
vitreous. Following a relatively rapid decline in concentration
between day 60 and 90, a second steady state is reached and
maintained through day 180 [82].
The Ozurdex dexamethasone-sustained delivery implant
has been approved by the United States Food and Drug
Administration (FDA) for the treatment of macular edema
associated with retinal vein occlusion (RVO) and for nonin-
fectious posterior uveitis.
3.1. Macular Edema Secondary to Retinal Vein Occlusion.
FDA approval was based on the therapeutic effects of dex-
amethasone implant investigated in a randomized, controlled
clinical trial (the Ozurdex GENEVA study) [83]. The study
design included two identical, randomized, prospective,mul-
ticenter, masked, and sham-controlled parallel groups. In the
double-masked 6-month initial treatment phase, 1.262 eyes
were randomized to either a sham procedure (𝑛 = 426)
or treatment with 350 𝜇g (𝑛 = 414) or 700𝜇g (𝑛 = 427)
dexamethasone implant. In the second open-label phase,
all eligible eyes received a 700 𝜇g dexamethasone implant
and were followed-up for additional 6 months. The primary
endpoint was the time to achieve over 15-letter improvement
(3 Snellen lines) in BCVA, and the secondary outcomes
included BCVA over the 6-month trial period and central
retinal thickness measured by OCT. The proportion of eyes
that achieved an improvement in visual acuity of 15 or more
letters was 22% in the 700 𝜇g group, 23% in the 350 𝜇g group,
and 13% in the shamgroup atmonth 3 (𝑃 < 0.001).These data
were no longer statistically significant at month 6. At the end
of the follow-up, the percentage of eyes that had experienced
a three-line gain was 41% in the 700𝜇g group, 40% in the
350 𝜇g group, and 23% in the sham group (𝑃 < 0.001). The
reduction in mean central retinal thickness was greater in the
700 𝜇g (208±201 𝜇m) and 350 𝜇g (177±197 𝜇m) groups than
in the sham group (85 ± 173 𝜇m) at month 3 (𝑃 < 0.001), but
not statistically significant at month 6. Twenty-one percent
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of the eyes affected by BRVO and the 17% of eyes with CRVO
required only a single treatment after 12 months of follow-
up. The study was also able to show that early treatment of
macular edema was more beneficial than delayed treatment
in restoring VA. A post hoc analysis suggested that eyes
treated within 90 days since the onset of cystoid macular
edema were more likely to improve than eyes in which the
treatment was instituted after this time point. In addition
to being the first FDA-approved therapy for macular edema
related to RVO, the dexamethasone DDS has been approved
by the EMA for macular edema in eyes with RVO in all of the
27 member states of the European Union.
3.2. Pseudophakic Cystoid Macular Edema and Macular
Edema Secondary toUveitis. Cystoidmacular edema is a con-
dition that can cause vision impairment after cataract surgery
or uveitis. In a randomized, prospective, single-masked,
controlled trial, 41 eyes with persistent macular edema from
uveitis or Irvine-Gass syndrome were randomized to receive
350 𝜇g, 700 𝜇g dexamethasone DDS, or observation. Results
have shown that dexamethasoneDDS is significantly effective
than observation. An improvement in visual acuity by three
or more lines was seen in 53.8% of 700 𝜇g-treated eyes
compared with 7.1% of observed eyes (𝑃 = 0.008). Moreover,
58% of eyes treated with the 700𝜇g implant have experienced
an improvement in angiographic leakage, compared with
only 8% of untreated eyes (𝑃 = 0.027) [79].
3.3. Diabetic Macular Edema. The efficacy of dexamethasone
DDS was evaluated in a randomized controlled study on
patients with persistent macular edema, defined as persis-
tence of macular edema for more than 90 days despite
treatment. A clinical trial enrolled 315 eyes with persistent
macular edema associated with numerous eye conditions,
including DME. One hundred seventy-two diabetic patients
were randomized to receive either a 350 or 700𝜇g implant
or observation. At 6 months, a visual acuity gain of at least
2 lines was obtained in 32.4%, 24.3%, and 21% of the eyes
receiving the 350-𝜇g implant, the 700-𝜇g implant, and obser-
vation, respectively. Treated eyes also had significantly greater
improvements in central macular thickness and fluorescein
leakage [84].
The CHAMPLAIN study was a prospective, multicenter
trial that enrolled adults with DME in a vitrectomized eye.
The authors reported that 21.4% of diabetic eyes gained at
least 10 letters and 42.9%of eyes had improved at least 5 letters
of visual acuity. Central macular thickness was decreased by
27% at week 13 and 9.6% at week 26 after the dexamethasone
intravitreal implant [85].
3.4. Age-Related Macular Degeneration. Intravitreal dexam-
ethasone is also used in clinical practice as a part of adjuvant
therapy to treat exudative AMD. Neovascular AMD is a mul-
tifactorial process that involves choroidal neovascularization
(CNV), vascular leakage, and inflammation. A triple therapy
approach to the treatment of wet AMD can be employed
when monthly treatment with vascular endothelial growth
factor inhibitors (anti-VEGF) has failed. Triple therapy (TT),
traditionally, consists of a vaso-occlusive procedure (photo-
dynamic therapy, PDT), an anti-VEGF agent, and a steroid.
The dose of dexamethasone used in numerous TT trials
ranges from 200𝜇g to 800𝜇g per injection. Several recent
studies have shown that TT may reduce the total number of
injections of anti-VEGF required and may stabilize vision in
those patients not responding to anti-VEGF monotherapies.
Augustin et al. investigated the efficacy and safety of TT
with PDT-V (42 J/cm2), intravitreal dexamethasone (800𝜇g),
and intravitreal bevacizumab (Avastin; Genentech, San Fran-
cisco, CA, USA, and Roche, Basel, Switzerland)(1.5mg). One
hundred-four eyes were included in this study. On average,
an increase in visual acuity of 1.8 lines was reported after
a mean follow up of 40 weeks. Eighteen eyes required an
additional intravitreal bevacizumab injection and 5 eyes
necessitated a second cycle of TT [86]. Bakri et al. reviewed
retrospectively the safety and efficacy of same-day therapy
with PDT-V (25 J/ cm2), intravitreal dexamethasone (200𝜇g),
and bevacizumab (1.25mg) in 31 eyes. Visual acuity improved
from 0.61 logMAR to 0.58 logMAR after a mean follow-
up of 13.7 months. Retreatment was given with a mean of
2.3 anti-VEGF injections and 0.3 repeated TT treatments
[87]. Ehmann and Garc´ıa studied prospectively the safety
and efficacy of same-day PDT-V (25 J/ cm2) and intravitreal
dexamethasone (800𝜇g). At 1 and 7 weeks, patients received
a bevacizumab (1.25mg) injection. Thirty-two eyes were
included and then followed-up for 12 months. Visual acuity
significantly improved from 0.74 ± 0.33 logMAR to 0.53 ±
0.32 logMAR (𝑃 < 0.005). The authors reported that a
proportion of 31% of the eyes had gained more than 3 lines
and a percentage of 6% of the eyes had experienced a loss of
more than 3 lines. Central macular thickness was decreased
from 328 ± 116 𝜇m to 216 ± 85 𝜇m (𝑃 < 0.001) at 12 months
of follow-up. The mean number of treatment cycles was 1.4,
while the mean number of bevacizumab injections was 2.8 at
the end of follow up [88].
Randomized controlled studies evaluating the use of the
dexamethasone implant in combination with ranibizumab
(Lucentis; Genentech Inc, San Francisco, CA, and Novartis
AG, Basel, Switzerland) in patients affected by neovascular
AMD have found that the implant significantly delayed or
reduced the need for repeated ranibizumab injection [89–91].
A 26-week multicenter open-label trial has been conducted
to evaluate efficacy and safety of dexamethasone implant in
combination with intravitreal ranibizumab in the treatment
of na¨ıve subjects affected by subfoveal CNV secondary to
AMD. All eyes received the dexamethasone implant at the
baseline. From week 2 study visit, eyes were eligible for treat-
ment with ranibizumab 0.5mg if BCVA had dropped 5 letters
or more from baseline. From weeks 4 to 22, ranibizumab
0.5mg could be given at the physician’s discretion. The
use of dexamethasone implant alone resulted in statistically
significant improvements in CRT from baseline as early as
week 1 and continued through week 4 (𝑃 < 0.001). In
addition, clinically significant improvements in BCVA and
fluorescein leakage were seen with the implant alone. With
the addition of ranibizumab as needed, statistically significant
improvements in CRT, BCVA, and FA leakage were more
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pronounced (𝑃 < 0.001). The percentage of eyes achieving at
least a 15-letter improvement from baseline BCVA was 4.5%
at week 4, 11.4% at week 8, 20.5% at week 22, and 15.9% at
week 26. Eighty-four percent of the patients did not require
rescue treatment with ranibizumab before 4 weeks. By the
end of the follow-up, a percentage of 45.5% required 3 or
fewer injections of ranibizumab and 20.4% of eyes needed 1
injection or fewer [91].
In the RADICAL Study, 162 patients were random-
ized to one of four treatment arms: double therapy with
reduced fluence PDT-V (25 J/ cm2) followed by ranibizumab,
reduced-fluence PDT-V (25 J/ cm2) followed by ranibizumab-
dexamethasone triple therapy, very low-fluence PDT-V (15 J/
cm2) followed by ranibizumab-dexamethasone triple ther-
apy, or ranibizumab monotherapy. The 24-month results
showed that mean visual acuity change from baseline was
not statistically different among the treatment groups. Mean
visual acuity in the double therapy group decreased by 2
ETDRS letters, in the TT half-fluence group improved by
2 letters, in the TT very-low fluence group improved by
0.3 letters, and in the monotherapy group improved by 3.8
letters. Through 24 months, patients in the TT half-fluence
group had a mean of 4.2 retreatments compared with 8.9
for the ranibizumab monotherapy group. However, when
computing the burden of the treatment protocol, the number
of individual treatments was 12.6 in the TThalf-fluence group
and 8.9 in the ranibizumab monotherapy group [92].
3.5. Noninfectious Vitritis. The dexamethasone DDS has also
proven beneficial in the treatment of noninfectious vitritis,
and has been recently approved by FDA and EMA for this
ocular condition. In a randomized, 26-week, sham-controlled
phase 3 trial, 229 eyes with noninfectious, intermediate,
or posterior uveitis were randomized to a single treatment
with a 700𝜇g dexamethasone DDS (𝑛 = 77), a 350 𝜇g
dexamethasone DDS (𝑛 = 76), or sham injection (𝑛 =
76).The dexamethasoneDDSwas significantlymore effective
than sham in removing vitreous haze. At week 8, a complete
resolution of vitreous haze was seen in 47% of 700𝜇g
dexamethasone group, 36% of 350 𝜇g dexamethasone group,
and 12% of sham group (𝑃 < 0.001). This beneficial effect
persisted through the end of the study. At all study visits,
the proportion of eyes with a gain of 15 or more letters from
baseline BCVA was significantly greater in dexamethasone-
treated groups than in sham-treated eyes [93].
4. Fluocinolone Acetonide
Fluocinolone acetonide is a synthetic corticosteroid with
potency similar to the glucocorticoid dexamethasone. It is
a corticosteroid with 1/24 the solubility of dexamethasone
in aqueous solution, which presumably would allow steroid
release over a much longer time period. Pharmacokinetic
studies have been conducted on rabbits implanted with 0.5
and 2mg implants and have found constant levels of fluoci-
nolone acetonide in the vitreous at all time points tested from
2 hours to 12months postimplantation, indicating zero-order
kinetics [94]. Vitreous concentrations were 7-8 times higher
in rabbits treated with 2mg implants compared with those
with 0.5mg implants. Steroid concentrations in the retina and
vitreous were considerably higher than those measured in
the aqueous humor, indicating posterior localization. Urine
and plasma levels of fluocinolone were below the threshold
of detection of 200 pg/mL, indicating the lack of systemic
absorption. The findings have been confirmed in human
trials, where fluocinolone was also undetectable in blood
samples [95]. These results reinforce the local activity of the
fluocinolone implant and the low risk of systemic adverse
effects of corticosteroids. The positive results reported in
several pilot, follow-up, and multicentered trials suggest that
the fluocinolone acetonide intravitreal implant may play a
significant role in the treatment of noninfectious posterior
uveitis, providing long-term control of posterior segment
inflammation. In addition to a decrease in the recurrence
of uveitis, these studies have showed an improvement in
visual acuity in implanted eyes and a reduction of the
use of combination therapy with systemic steroids or local
injections. As the result of clinical trials demonstrating safety
and efficacy, the United States FDA approved the 0.59mg
fluocinolone acetonide intravitreal implant (Retisert, Bausch
& Lomb, Rochester, NY) as a first choice for the treatment of
noninfectious posterior uveitis in April 2005 [96].
4.1. Diabetic Macular Edema. Recently, fluocinolone ace-
tonide implants have been studied for the treatment of
other ocular conditions, including DME. Iluvien (Alimera
Sciences, Alpharetta, GA, USA) has been developed as a
nonbiodegradable intravitreal insert for the sustained deliv-
ery of fluocinolone acetonide to the posterior segment. It
is designed to be injected with a 25-gauge needle through
the pars plana. The device is not secured to the sclera but
remains free-floating in the vitreous. The Iluvien contains
approximately 190 𝜇g of fluocinolone acetonide. Depending
on its formulation, the insert can deliver a low dose of
approximately 0.2 𝜇g per day, with a delivery lifespan of
more than 2 years, or a high dose of approximately 0.5 𝜇g
per day, with a lifespan of approximately 18 months. The
FAME study consisted of two 36-month phase 3 clinical trials
that investigate the safety and the efficacy of two doses of
FA implant in patients affected by DME. In this study 956
patients with DME were randomized to either receive a high
dose insert (0.5 𝜇g/day), a low-dose insert (0.2 𝜇g/day), or a
sham insertion. These trials have reported that 26.8% of low
dose FA group and 26.2% of high dose FA group gained 15
or more letters at 24 months compared with 14.7% of patients
randomized to control (𝑃 = 0.029 and 𝑃 = 0.032, resp.). At
36 months, an improvement in visual acuity by three or more
lines occurred in 28.7%, 27.8%, and 18.9%of eyes, respectively.
Mean (±SD) reductions in central macular thickness were
185 ± 174 𝜇m in the high dose FA group, 180 ± 160 𝜇m in
the low dose FA group, and 142 ± 152 𝜇m in the sham group
at the end of follow-up period (𝑃 < 0.001, 𝑃 < 0.005 and
𝑃 < 0.001, resp.). Among patients with a duration of DME
that is more than 3 years (long duration), a proportion of eyes
showing a gain of 15 letters or more was 13.4% of patients in
sham group compared with 34% in the low dose FA group
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Figure 1: Distribution of change in visual acuity (ETDRS letters) between baseline and month 12 (unless otherwise specified) for large,
controlled, and randomized clinical trials investigating steroids in diabetic macular edema and macular edema secondary to retinal vein
occlusion. GENEVA (6 months): 700 𝜇g dexamethasone implant. SCORE: 4mg intravitreal triamcinolone acetonide. DRCR prot B: 4mg
intravitreal triamcinolone acetonide.DRCRprot I: 4mg intravitreal triamcinolone acetonide plus laser photocoagulation. FAME (24months):
0.2 𝜇g/day fluocinolone implant. GENEVA and FAME publications did not disclose distribution of change other than the percentage of
patients showing a ≥ 15 ETDRS letters gain.
(𝑃 < 0.001) and 28.8% in high dose FA group (𝑃 = 0.002).
An improvement of three or more lines in patients with DME
for less than 3 years (short duration) occurred in 27.8% of
the eyes in the sham group, 22.3% of the eyes in low dose
FA group, and 26.4% of the eyes in high dose FA group, but
the difference was not significant.Themean change in BCVA
letter score between baseline and month 36 in long duration
DME subjects was 1.8 in the sham group compared with 7.6
in low dose FA group (𝑃 < 0.004) and 6.2 in high dose
FA group (𝑃 < 0.024). Similar and not significant anatomic
outcomes were seen in patients with short a long duration
DME [97]. FA implant is still not approved by FDA, but it
has recently receivedmarketing authorization inUK,Austria,
France, Germany, Spain, and Portugal for the treatment of
vision impairment due to chronic DME unresponsive to
other available therapies.
4.2. Other Conditions. Iluvien insert is currently in phase
II clinical trials for the treatment of dry AMD, macular
edema secondary to RVO and in several studies comparing
0.2mg and 0.5mg fluocinolone acetonide intravitreal insert
and ranibizumab in neovascular AMD.
A summary of change in visual acuity from studies
investigating steroids in DME andmacular edema secondary
to RVO is presented in Figure 1.
5. Safety of Intravitreal Corticosteroids
5.1. Triamcinolone Acetonide. Potential complications of
intravitreal corticosteroid treatment are divided into steroid-
related and injection-related adverse effects. Steroid-related
side effects most commonly include cataract formation and
an intraocular pressure (IOP) increase. Injection-related side
effects include retinal detachment, endophthalmitis, and
pseudoendophthalmitis.
5.1.1. Postinjection Infectious Endophthalmitis. Infectious
endophthalmitis is one of the most serious complications
of intravitreal injection of TA, with the reported risk
per injection ranging from 0.1% to 1.6% [20]. Many
studies suggest that this relatively high rate of infectious
endophthalmitis may be attributed to the techniques used
for injection. If the injection is performed under sterile
conditions, the risk of an infection may be inferior [98, 99].
5.1.2. Postinjection Pseudoendophthalmitis. Several studies
have described noninfectious endophthalmitis after intravit-
real injection of TA [98, 99]. Postinjection pseudoendoph-
thalmitis is present if TA crystals are washed from the
vitreous cavity into the anterior chamber and settled down in
the inferior anterior chamber angle mimicking a hypopyon.
According to reports, this complication occurs in 0.2%–
6.7% of the eyes following treatment. TA crystals in the
anterior chamber usually disappear spontaneously and may
not need to be removed. There have been no reports so
far showing corneal endothelial damage or damage to the
trabecularmeshwork by the crystals [100]. Some investigators
have hypothesized that the presence of benzyl alcohol, a
bacteriostatic preservative in some commercially available
TA, leads to an increased risk of sterile endophthalmitis
[101].
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5.1.3. PostinjectionOcularHypertension. Anumber of reports
have described intraocular pressure (IOP) elevation as the
most common adverse event of intravitreal TA [102, 103].
Mild to moderate IOP elevation was seen in 28%–42%
of patients, typically within the first 3 months following
injection. This condition is usually controlled with topical
agents alone. About 1% of the patient requires surgical
treatment. Selective laser trabeculoplasty (SLT) is a treatment
alternative or adjunct to medical therapy. Comparing studies
using different doses of TA for intravitreal injection may
suggest that the risk of IOP rise appears to be higher due
to the prolonged elevated concentrations that are achieved
intraocularly. If further studies confirm the assumption that
the frequency of secondary ocular hypertension after an
intravitreal TA injection may not markedly depend on the
dose used, one may assume that even relatively low TA doses
are already high enough to occupy all steroid receptors. Some
authors suggest that a premedication with topical steroids
may be useful to identify possible steroid-responders and
excluding those from intravitreal TA treatment that may
lower the incidence of IOP elevation [104].
5.1.4. Post Injection Cataract. Steroid-induced cataract is
a common side effect of intravitreal TA. A recent study
reported that in the elderly population intravitreal, high-
dose injections of TA lead to clinically significant cataract
with eventual cataract surgery in about 15–20% of the
eyes within about one year after the intravitreal injection
[105]. Jonas et al. concluded that eyes with an elevation of
IOP after intravitreal TA have a very high risk of rapidly
experiencing posterior subcapsular lens opacities [106]. This
strong association suggests a similar mechanism responsible
for the development of steroid-induced posterior subcapsular
cataract and for the elevation of IOP. A study suggested that a
single intravitreal TA induces posterior subcapsular cataract
development, whereas multiple injections result in all-layer
cataract progression [107].
5.1.5. Rhegmatogenous Retinal Detachment. Apotential com-
plication of the intravitreal TA injection may be a rheg-
matogenous retinal detachment [108]. Triamcinolone ace-
tonide, injected into the vitreous cavity, leads to a change
in the structure of the vitreous body and the abnormal
vitreous may exert traction on the retina. In particular,
this is supposed for the inferior midperipheral area of the
vitreoretinal interface where the TA crystals remain in the
preretinal vitreal cortex, for superior midperipheral and
peripheral regionswhere a vitreous tractionmight be induced
by the weight of the TA crystals settled at 6 o’ clock and for the
far periphery of the fundus where the vitreous, incarcerated
into the injection site, causes retinal traction.
5.1.6. Toxic Effects. Previous studies in rabbit found that
preservatives in the vehicle for suspension of crystalline
steroid, rather than steroid itself, could be toxic to the
rabbit retina and lens and that the vehicle is not totally
responsible for the toxicity, but may initiate TA-dependent
toxicity [109]. Direct toxic effects of TA on the retina and
optic nerve have not yet been observed, independently of the
dose used. Triamcinolone acetonide has been shown to be
toxic to retinal pigment epithelial cells in vitro [110], whereas
ex vivo [111] and in vivo [112] studies have failed to show
any significant toxicity to the retina. Because TA is a heavy
depot formulated suspension, it settles in the inferior vitreous
cavity. Whereas there is certainly distribution of the drug
throughout the vitreous cavity due to diffusion and constant
eyemovements, it is possible that the drug does not distribute
equally in the vitreous cavity and that the concentration of
the drug at the macula is different (presumably lower) than
in the inferior retinal periphery [113]. Yeung et al. reported a
possible cytotoxic effect of TA, causing a significant reduction
in cell numbers throughout thewhole range of concentrations
when retinal pigment epithelium cells were exposed to it for
more than one day [114].
5.1.7. Systemic Safety. In the randomized study from
DRCR.net, comparing laser photocoagulation to
ranibizumab in combination with laser and intravitreal
TA associated with laser, no evidence suggest that the
administration of TA is associated with an increased risk of
systemic adverse events, including stroke or cardiac events.
Two-year incidence of nonfatal myocardial infarction was
3% in the laser alone group, 1% in the ranibizumab-laser
group, and 3% in the TA-laser group. Any cardiovascular
event, as defined by Antiplatelet Trialists’ Collaboration
(ATC), occurred in the 12% in the laser alone group, 5% in
the ranibizumab-laser group, and 6% in the TA-laser group
[61]. Reports of systemic adverse events were similar between
the SCORE-BRVO and CRVO trial groups. The medical
dictionary for regulatory activities system/organ class of
infection and infestations had the highest incidence through
month 12, with 10%, 15-16%, and 15–19% of participants
reporting at least 1 event in the standard care, 1-mg TA, and
4-mg TA groups, respectively [46, 47].
5.2. Dexamethasone. The safety and tolerability of a
sustained-release implant are particularly important due
to the long duration of exposure to the drug and the drug
vehicle. The safety of the implant may be divided into several
categories: complications arising from the implantation
procedure; toxicity or immunoreactivity associated with
exposure to the implant polymer; and ocular adverse events
associated with exposure to the agent itself, such as cataract
formation and IOP increase.
5.2.1. Traumatic Implantation. Several adverse events were
believed to be related to traumatic implantation. A recent
study compared the safety profile of surgical implantation
with that of a novel proprietary applicator device. Use of
the applicator device was associated with a lower overall
incidence of ocular adverse events (68.4% versus 90%),
although this difference was not statistically significant. Of
note, there were no reports of vitreous hemorrhage in the
applicator group, compared with 2 out of 10 patients in
the incisional group who experienced this complication.
However, the study was insufficiently powered to determine
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a statistically significant difference for this or any other
infrequently occurring adverse event [115].
5.2.2. Toxic Effects. Early animal studies determined that
a high concentration of dexamethasone could be achieved
intravitreally without any clinical, histological, or electro-
physiological toxicity [80]. Increasing levels of retinal toxicity
have been reported at doses above 800 𝜇g administered to
rabbits. Electroretinographic studies confirmed no change in
normal retinal physiology [80].
5.2.3. Postimplant Ocular Hypertension. A number of studies
have described intraocular pressure (IOP) elevation as a com-
mon adverse event of dexamethasone implant. Kuppermann
et al. reported that an elevation of IOP more than 10mmHg
occurred in less than 20% of each groups treated with
dexamethasone implant. This condition is usually controlled
with topical agents alone [84]. The recent data presented by
GENEVA study have shown transient instances of elevated
IOP, which were managed either by observation or with
topical medications alone. Typically, IOP reached a peak at
2 months, decreasing steadily over the next 4 months. At this
peak time point, the authors reported that 16% of all patients
had a pressure of greater than 25mmHg. The proportion of
patients using ocular antihypertensive agents increased from
6% at study entry to 24% at 6 months among all patients in
the treatment group. An increase of at least 10mmHg from
baseline was seen in 12.6% of study eyes at 2 months after
the first dexamethasone implant and 15.4% of study eyes at
2 months after the second dexamethasone implant. At the
end of the 12-month study period, 32.8% of retreated patients
had at least a 10mmHg increase from baseline and 14 eyes
required laser or surgery to reduce intraocular pressure [83].
5.2.4. Postimplant Cataract Formation. Comparing patients
treated with 0.35mg or 0.7mg doses of dexamethasone
implant with a control group, many randomized clinical trial
have recorded that the rate of cataract formation was not
significantly different in any treatment group than in the
control group at the end of 6 months of follow-up [83, 84].
However, GENEVA study reported that after 12 months of
follow-up, cataracts were listed in 29.8% of phakic study eyes
in the retreated DEX 0.7/0.7 group, 19.8% of the DEX 0.35/0.7
group, and 10.5% of the delayed treatment (sham/0.7) group
(𝑃 = 0.001) [83].
5.2.5. Fluocinolone Acetonide. Randomized clinical trials
evaluating the safety of Retisert for the treatment of uveitis
have reported that a proportion from 50% to 90% of patients
experienced an adverse event after implantation, most com-
monly cataract formation and increased IOP. Within 2 years
of implantation, nearly 100% of phakic eyes required cataract
surgery and one third of patients required a glaucoma sur-
gical procedure. Other adverse events included ptosis, eyelid
edema, conjunctival hemorrhage, chemosis, corneal edema,
vitreous opacities, vitreous hemorrhage, macular edema,
retinal hemorrhage, hypotony, and choroidal detachment
[95, 96].
In the randomized study from FAME comparing sham
injection, high-dose and low-dose of fluocinolone implant
presented two ocular adverse events: cataract progression
and intraocular pressure (IOP) increase. The most common
adverse event was cataract, which was listed in 42.7% of
the low-dose group, 51.7% of the high-dose group, and 9.7%
of the sham group. Of those patients who were phakic at
baseline, cataract surgery was performed in 80.0% (low dose)
and 87.2% (high dose) of patients in the fluocinolone groups
compared with 27.3% in the sham group. During the study
elevation of IOP, more than 30mmHg was recorded in 37.1%
of patients in the low-dose group, 45.5% in the high-dose
group, and 11.9% in the sham group. Laser trabeculoplasty
was performed in 2.5% of the high-dose group, 1.3% of the
low-dose group, and 0% of the sham group. Incisional IOP-
lowering surgery was done in 8.1% of the high-dose group,
4.8% of the low-dose group, and 0.5% of the sham group [97].
6. Conclusions
Intravitreal steroid injection appears to be an effective option
for the treatment of macular edema secondary to various
etiologies. The rationale for using steroids is due to anti-
inflammatory, antiedematous, and antiangiogenic properties.
An increasing number of ophthalmologists use intravitreal
steroids for the treatment of various posterior segment
disorders, especially when traditional therapeutic methods
have failed. Triamcinolone acetonide is a drug that has largely
been studied in many clinical trials for the treatment of these
ocular conditions. However, the need for frequent intravitreal
injections and the potential side effects have focused attention
on the development of alternative systems for the delivery
of ophthalmic medications. A variety of methods have been
proposed that achieve longer duration of pharmacologic
effect with lower administration frequency and minimal
side effects. Novel agents including preservative-free and
sustained-release intravitreal implants such as Ozurdex and
Iluvien are currently approved for ocular use and are being
further evaluated for the treatment of RVO,DME, uveitis, and
AMD. Due to a potential for greater potency, dexamethasone
and fluocinolone acetonide are being evaluated alone or in
combination with anti-VEGFs as promising options in the
emerging armamentarium for the treatment of several retinal
diseases.
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